TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06973629: Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

Sponsor: Brainstorm-Cell Therapeutics · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 200 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$14,040,960

Rescue Site Savings

+$9,287,510

Unlock Full NCT06973629 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06973629 Rescue Dossier →